New leadership for Novo Nordisk

By Megan Brodie 2 years ago | In Companies, People
  • 2 years ago
Incoming Novo Nordisk Oceania Vice President Cem Ozenc.

17 June 2022

Novo Nordisk will have new leadership in Oceania by September as its current Vice President and General Manager Jeppe Theisen prepares to head home to Denmark and the company’s APAC regional Corporate Vice President prepares to move from Dubai to Australia to take up Theisen’s current VP role.

After 15 years with Novo, Cem Ozenc took on the role of Corporate Vice President of Commercial Affairs and Strategy for the APAC region in April 2020, managing the regional leadership role from Dubai.

Ozenc took to LinkedIn to announce to his 6,000 followers he would take over from Theisen in September, the latter moving back to Denmark after eight years in APAC leadership roles.

“A little update here: taking a flight to down under soon!” the Turkish-born Ozenc announced to his followers.

“After five amazing years in Dubai and having worked with extremely competent, hard-working and fun-loving individuals first in Region AAMEO and later in Region APAC offices, I am very grateful and extremely excited to share with all of you that I will be moving to Sydney, Australia on 1 September to head up our Novo Nordisk Oceania organisation

“I will be taking the baton from my great friend and colleague, Jeppe Theisen, who has, together with a strong high-performance Oceania team, brought absolutely amazing business results, strong purpose to serve the patients and truly winning spirit to Novo Nordisk Oceania in the last three years.

“There are over two million people living with diabetes and over eight million people with obesity and many more with other serious chronic and rare diseases living in Australia & New Zealand.

“Novo Nordisk is well-positioned to provide innovative treatments to patients and healthcare professionals to drive a sustainable change for the long run. I am looking very much forward to getting to know each and every member of Oceania team and to support the continuation of the great work by the strong organisation in Oceania in years to come.”

Ozenc has several Harvard Business School qualifications, including one obtained last year in obesity strategy. He joined Novo Nordisk in Turkey in 2005 as a diabetes Product Manager, moving briefly to Denmark in 2008 then to Jordan as country General Manager in 2012.

In 2014, Ozenc became General Manager for Novo in Iran and took on a regional leadership role as Vice President of Commercial Affairs and Strategy in 2017. His current APAC VP role gives him functional responsibility for marketing, market access, pricing, sales, commercial effectiveness and business development across 20 APAC countries.

Ozenc will no doubt be tasked with securing reimbursement for WEGOVY (semaglutide), the company’s diabetes shot proving so successful in weight loss that it prompted a social media storm, triggering a national product shortage. The PBAC rejected a reimbursement submission from Novo in March, and the TGA is yet to approve the obesity indication despite it being approved in Europe and the US.

Outgoing Novo Nordisk Oceania VP Jeppe Theisen

Theisen will return to Denmark with his family in the next few months to take on the role of General Manager for Novo Nordisk Denmark/Iceland.

“What a great journey the last eight years have been across the world with my family – and with Novo Nordisk,” Theisen posted on LinkedIn.

“I am excited to be returning back with my family to our home, Denmark, very soon. I am equally excited and honoured – a special place for Novo Nordisk as our home market and me as this was where I started my career in Novo Nordisk as Biopharm Director 12 years ago.”

“I am looking forward to building on the strong work and being part of the great team in Denmark.”

Theisen remarked leaving “such a talented team in Oceania that has driven growth to the next level and truly has been driving change for people living with diabetes, obesity and rare diseases” would be tough, but he welcomed Ozenc to the role.

“I’m at the same time glad that my fantastic colleague Cem Ozenc will be taking over the leadership of Novo Nordisk Oceania and surely will lead the team to go from strength to strength – all the best,” Theisen said.

Along with the challenge of reimbursement for obesity, Novo also had another semaglutide product approved in RYBELSUS, while its new growth hormone product SOGROYA (somapacitan) is working its way through PBS pricing negotiations, securing a deal likely to be one of the last achievements of Theisen before he leaves Australian shores.

©MedNews 2022

Leave a Reply